Voluntis: Results of the eCO Trial Published in the Journal of Clinical Oncology Informatics
July 16 2018 - 12:00PM
Business Wire
Regulatory News:
Voluntis (Paris:VTX) (the “Company” or “Voluntis”
- ticker: VTX - ISIN Code: FR 0004183960), a company
specialized in digital therapeutics, today announces that results
for eCO, the digital therapeutic it developed for women with
ovarian cancer in partnership with AstraZeneca and the National
Cancer Institute, have been published in the Journal of Clinical
Oncology (JCO®) Clinical Cancer Informatics.
The study, published as “Technology APPlications: Use of digital
health technology to enable drug development,” examined the
feasibility, usability and perceived satisfaction with eCO
(eCediranib-Olaparib), a mobile application for side effect
monitoring and reporting, in women with recurrent ovarian cancer.
The eCO app was specifically designed to assist in managing acute
treatment-related events such as hypertension and diarrhea, which
are most often associated with treatment discontinuation, the need
for drug holidays or dose interruptions/modifications. Users logged
their data and received real-time treatment recommendations for
their symptom management. Their data was also sent simultaneously
to their care team who could follow their progress remotely via a
web portal.
Symptoms reported via eCO allowed rapid provider response and a
positive overall patient experience. Survey analysis showed that
patients had statistically significant, positive responses to the
use of the eCO application. Patients indicated eCO use made them
feel more involved in their care and better connected to their
healthcare team.
“The publication of these positive clinical results in the JCO®
Clinical Cancer Informatics journal suggests there is increasing
interest for digital adoption in oncology care,” said Pierre
Leurent, CEO of Voluntis. “We design solutions to help people
with cancer to better manage their side effects while they stay
connected to their care team. We believe that digital therapeutics
will one day become part of routine clinical oncology
practice.”
AstraZeneca and Voluntis formed a partnership in 2015, in
collaboration with the NCI, to develop an innovative digital
solution to support women undergoing treatment for recurrent
platinum-sensitive high-grade ovarian cancer in clinical trials of
cediranib plus olaparib.
About Voluntis
Voluntis creates digital therapeutics that empower people
suffering from chronic conditions to self-manage their treatment
every day, thus improving real-world outcomes. Combining mobile and
web apps, Voluntis’ solutions deliver personalized recommendations
to the patient and the care team that so that they can, for
example, adjust treatment dosage, manage side effects or monitor
symptoms. These real-time recommendations are based on digitized
clinical algorithms. Leveraging its Theraxium technology platform,
Voluntis has designed and operates multiple digital therapeutics.
These include Insulia® and Diabeo® in diabetes as well as eCO and
ZEMY in oncology. Voluntis has long-standing partnerships with
leading life science companies such as Roche, AstraZeneca, Sanofi
and Onduo. Based out of Boston and Paris, France, Voluntis is a
founding member of the Digital Therapeutics Alliance.
For further information: http://www.voluntis.com
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. The Company also is selectively active
in the areas of autoimmunity, neuroscience and infection.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180716005511/en/
VoluntisMatthieu Plessis, +33 (0)1 41 38 39
20Chief Financial
Officerinvestisseurs@voluntis.comorNewCapInvestor
relationsMarc Willaume / Tristan Roquet Montégon+33 (0)1
44 71 94 94voluntis@newcap.euorNewCapMedia
relationsNicolas Merigeau, +33 (0)1 44 71 94
98voluntis@newcap.euorCorporate mediasVoluntisAmélie
Janson, (617) 245 41 25press@voluntis.com